<DOC>
	<DOCNO>NCT00644800</DOCNO>
	<brief_summary>To assess efficacy , safety , tolerability intramuscular ziprasidone treatment acute exacerbation non-organic psychosis etiology , include schizophrenia , acute mania , delusional disorder others .</brief_summary>
	<brief_title>A Study Efficacy Safety Intramuscular Ziprasidone Followed Oral Ziprasidone Treatment Psychosis</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Schizophrenia , Paranoid</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<criteria>Hospitalized patient psychosis Eligible intramuscular treatment Miminum score 60 PANSS , score 14 sum PANSS excitation score score least 4 1 follow item : poor control impulse , tension , hostility , uncooperativeness excitation . Treatment antidepressant mood stabilizer within seven day prior enrollment ; monoamine oxidase inhibitor ( MAOIs ) moclobemide , period must two week ; fluoxetine , five week Resistance conventional antipsychotic agent A history epilepsy A diagnosis abuse substance within previous 3 month accord DSMIV criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>